Objective: Intravenous N-methyl-d-aspartate (NMDA) antagonists have shown promising
results in rapidly ameliorating depression symptoms, but placebo-controlled trials of oral …

Objective: To determine the differences between escitalopram and citalopram in the
treatment of patients with major depressive disorder across a range of baseline severity of …

Symptoms of depression and anxiety are common in patients with substance use disorders
(Meyer 1986; Schuckit 1986). In the general population, mood and anxiety disorders convey …

Memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease
with a good safety profile, is increasingly being studied in a variety of non-dementia …

E ASSOCIATION between alcoholism and de-pression has long been recognized." It is,
therefore, not surprising that tricyclic antidepressants have been used to treat alcoholic …

Background Memantine is effective in the treatment of behavioral disturbances in patients
with Alzheimer's disease. It has not yet been fully determined which behavioral disturbances …

Background. Escitalopram has been proven safe and efficacious in the treatment of major
depressive disorder (MDD) in short-term studies. The long-term clinical tolerability and …

We conducted a systematic review and meta-analysis on whether memantine was beneficial
for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar …

Introduction Behavioural symptoms are common in moderate to severe Alzheimer's disease
(AD). We have analysed the databases of two randomised studies with regard to the effects …

Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-D-aspartate
receptors, approved for the treatment of moderate to severe Alzheimer's disease (AD) …